Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 21,800 shares at $129.35 ($2.9M) on 2018-04-24, disclosed to the SEC on 2018-04-26.
Open-market sale of $2.9M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $129.35 | 1,717 | $222K | 7.8% |
| 2 | $129.35 | 1,717 | $222K | 7.8% |
| 3 | $130.62 | 1,283 | $168K | 5.9% |
| 4 | $130.62 | 1,283 | $168K | 5.9% |
| 5 | $131.76 | 1,500 | $198K | 6.9% |
| 6 | $132.54 | 2,490 |
| $330K |
| 11.6% |
| 7 | $132.54 | 2,490 | $330K | 11.6% |
| 8 | $133.49 | 510 | $68K | 2.4% |
| 9 | $133.49 | 510 | $68K | 2.4% |
| 10 | $128.30 | 800 | $103K | 3.6% |
| 11 | $128.30 | 800 | $103K | 3.6% |
| 12 | $129.44 | 800 | $104K | 3.6% |
| 13 | $130.71 | 2,400 | $314K | 11.0% |
| 14 | $131.84 | 3,400 | $448K | 15.7% |
| 15 | $132.53 | 100 | $13K | 0.5% |
| Total | $131.07 avg | 21,800 | $2.9M | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $2.9M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $5.4M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $5.0M | — | Filing → |